Tehran University of Medical Sciences

Science Communicator Platform

Stay connected! Follow us on X network (Twitter):
Share By
Safety and Effectiveness of Azithromycin in Patients With Covid-19: An Open-Label Randomised Trial Publisher Pubmed



Sekhavati E1 ; Jafari F2, 3 ; Seyedalinaghi S4 ; Jamalimoghadamsiahkali S5 ; Sadr S2 ; Tabarestani M6 ; Pirhayati M3 ; Zendehdel A7 ; Manafi N3 ; Hajiabdolbaghi M8 ; Ahmadinejad Z9 ; Kouchak HE8 ; Jafari S8 ; Khalili H10 Show All Authors
Authors
  1. Sekhavati E1
  2. Jafari F2, 3
  3. Seyedalinaghi S4
  4. Jamalimoghadamsiahkali S5
  5. Sadr S2
  6. Tabarestani M6
  7. Pirhayati M3
  8. Zendehdel A7
  9. Manafi N3
  10. Hajiabdolbaghi M8
  11. Ahmadinejad Z9
  12. Kouchak HE8
  13. Jafari S8
  14. Khalili H10
  15. Salehi M8
  16. Seifi A8
  17. Golestan FS11
  18. Ghiasvand F9

Source: International Journal of Antimicrobial Agents Published:2020


Abstract

As no specific pharmacological treatment has been validated for use in coronavirus disease 2019 (COVID-19), we aimed to assess the effectiveness of azithromycin (AZM) in these patients at a referral centre in Iran. An open-label, randomised controlled trial was conducted on patients with laboratory-confirmed COVID-19. A total of 55 patients in the control group receiving hydroxychloroquine (HCQ) and lopinavir/ritonavir (LPV/r) were compared with 56 patients in the case group who in addition to the same regimen also received AZM. Patients with prior cardiac disease were excluded from the study. Furthermore, patients from the case group were assessed for cardiac arrythmia risk based on the American College of Cardiology (ACC) risk assessment for use of AZM and HCQ. The main outcome measures were vital signs, SpO2 levels, duration of hospitalisation, need for and length of intensive care unit admission, mortality rate and results of 30-day follow-up after discharge. Initially, there was no significant difference between the general conditions and vital signs of the two groups. The SpO2 levels at discharge were significantly higher, the respiratory rate was lower and the duration of admission was shorter in the case group. There was no significant difference in the mortality rate between the two groups. Patients who received AZM in addition to HCQ and LPV/r had a better general condition. HCQ+AZM combination may be beneficial for individuals who are known to have a very low underlying risk for cardiac arrhythmia based on the ACC criteria. © 2020 Elsevier Ltd and International Society of Antimicrobial Chemotherapy
Related Docs
View other Related Docs
1. Real Clinical Practice and Therapeutic Management Following Covid-19 Crisis in Two Hospitals in Iran: A Statistical and Conceptual View, Tanaffos (2020)
2. Effect of Covid-19 Medications on Corrected Qt Interval and Induction of Torsade De Pointes: Results of a Multicenter National Survey, International Journal of Clinical Practice (2021)
3. A Review on Currently Available Potential Therapeutic Options for Covid-19, International Journal of General Medicine (2020)
Experts (# of related papers)
View all Related Experts
Hossein Khalili (3)
Fereshte Ghiasvand (2)
Other Related Docs
4. Clinical Outcomes of Patients With Mild Covid-19 Following Treatment With Hydroxychloroquine in an Outpatient Setting, International Immunopharmacology (2021)
5. Sars-Cov-2: From the Pathogenesis to Potential Anti-Viral Treatments, Biomedicine and Pharmacotherapy (2021)
6. Safety and Efficacy of Hydroxychloroquine and Chloroquine in Treatment of Covid-19: A Rapid Review of Evidence, Health Technology Assessment in Action (2020)
7. Current Treatments and Therapeutic Options for Covid-19 Patients: A Systematic Review, Infectious Disorders - Drug Targets (2022)
8. Novel Therapeutic Approaches for Treatment of Covid-19, Journal of Molecular Medicine (2020)
9. Covid-19 Treatment Success After Repeat Courses of Azithromycin: A Report of Three Cases, Infectious Disorders - Drug Targets (2021)
10. An Overview on the Treatments and Prevention Against Covid-19, Virology Journal (2023)
11. Comparing Outcomes of Hospitalized Patients With Moderate and Severe Covid-19 Following Treatment With Hydroxychloroquine Plus Atazanavir/Ritonavir, DARU# Journal of Pharmaceutical Sciences (2020)
12. Can Anti-Parasitic Drugs Help Control Covid-19?, Future Virology (2022)
13. Interferon Β-1B in Treatment of Severe Covid-19: A Randomized Clinical Trial, International Immunopharmacology (2020)
14. Immunomodulatory-Based Therapy As a Potential Promising Treatment Strategy Against Severe Covid-19 Patients: A Systematic Review, International Immunopharmacology (2020)
15. Covid-19: Our Current Knowledge of Epidemiology, Pathology, Therapeutic Approaches, and Diagnostic Methods, Anti-Cancer Agents in Medicinal Chemistry (2021)
16. Covid-19: A Systematic Review and Update on Prevention, Diagnosis, and Treatment, MedComm (2022)
17. The Situation of Small Molecules Targeting Key Proteins in Combatting Sars-Cov-2: Synthesis, Metabolic Pathway, Mechanism of Action, and Potential Therapeutic Applications, Mini-Reviews in Medicinal Chemistry (2022)
18. Covid-19, an Early Investigation From Exposure to Treatment Outcomes in Tehran, Iran, Journal of Research in Medical Sciences (2021)
19. Antiviral Therapy Inmanagement of Covid-19: A Systematic Review on Current Evidence, Archives of Academic Emergency Medicine (2020)
20. Comparison of the Eight Different Treatment Regimens for the Hospitalized Patients With Covid-19: A Retrospective Cohort Study, Journal of Cellular and Molecular Anesthesia (2021)